SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-17-011347
Filing Date
2017-11-03
Accepted
2017-11-03 16:31:20
Documents
51
Period of Report
2017-09-30

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT f10q0917_actiniumpharma.htm 10-Q 498764
2 CERTIFICATION f10q0917ex31i_actiniumpharm.htm EX-31.1 11855
3 CERTIFICATION f10q0917ex31ii_actiniumpharm.htm EX-31.2 12992
4 CERTIFICATION f10q0917ex32i_actiniumpharm.htm EX-32.1 4689
5 CERTIFICATION f10q0917ex32ii_actiniumpharm.htm EX-32.2 5940
  Complete submission text file 0001213900-17-011347.txt   2971190

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE FILE atnm-20170930.xml EX-101.INS 459687
7 XBRL SCHEMA FILE atnm-20170930.xsd EX-101.SCH 36950
8 XBRL CALCULATION FILE atnm-20170930_cal.xml EX-101.CAL 25315
9 XBRL DEFINITION FILE atnm-20170930_def.xml EX-101.DEF 131489
10 XBRL LABEL FILE atnm-20170930_lab.xml EX-101.LAB 355178
11 XBRL PRESENTATION FILE atnm-20170930_pre.xml EX-101.PRE 224399
Mailing Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016
Business Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016 646-677-3875
Actinium Pharmaceuticals, Inc. (Filer) CIK: 0001388320 (see all company filings)

IRS No.: 880378336 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36374 | Film No.: 171176836
SIC: 2834 Pharmaceutical Preparations